Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

TNGX vs RVMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TNGX
Tango Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$3.21B
5Y Perf.+128.0%
RVMD
Revolution Medicines, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$32.12B
5Y Perf.+334.1%

TNGX vs RVMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TNGX logoTNGX
RVMD logoRVMD
IndustryBiotechnologyBiotechnology
Market Cap$3.21B$32.12B
Revenue (TTM)$62M$0.00
Net Income (TTM)$-102M$-1.37B
Gross Margin97.3%
Operating Margin-178.4%
Total Debt$34M$159M
Cash & Equiv.$112M$384M

TNGX vs RVMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TNGX
RVMD
StockSep 20May 26Return
Tango Therapeutics,… (TNGX)100228.0+128.0%
Revolution Medicine… (RVMD)100434.1+334.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: TNGX vs RVMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TNGX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Revolution Medicines, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TNGX
Tango Therapeutics, Inc.
The Growth Play

TNGX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.

  • Rev growth 48.3%, EPS growth 26.9%, 3Y rev CAGR 35.9%
  • Lower volatility, beta 1.81, Low D/E 9.7%, current ratio 16.32x
  • 48.3% revenue growth vs RVMD's -98.6%
Best for: growth exposure and sleep-well-at-night
RVMD
Revolution Medicines, Inc.
The Income Pick

RVMD is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.08
  • 422.7% 10Y total return vs TNGX's 130.9%
  • Beta 1.08, current ratio 7.14x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTNGX logoTNGX48.3% revenue growth vs RVMD's -98.6%
Quality / MarginsRVMD logoRVMD2.8% margin vs TNGX's -162.9%
Stability / SafetyRVMD logoRVMDBeta 1.08 vs TNGX's 1.81
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)TNGX logoTNGX+17.7% vs RVMD's +303.5%
Efficiency (ROA)TNGX logoTNGX-36.3% ROA vs RVMD's -59.1%, ROIC -38.5% vs -54.3%

TNGX vs RVMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TNGXTango Therapeutics, Inc.
FY 2025
Collaboration Revenue
100.0%$62M
RVMDRevolution Medicines, Inc.
FY 2022
Collaboration Revenue Member
100.0%$35M

TNGX vs RVMD — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTNGXLAGGINGRVMD

Income & Cash Flow (Last 12 Months)

TNGX leads this category, winning 1 of 1 comparable metric.

TNGX and RVMD operate at a comparable scale, with $62M and $0 in trailing revenue.

MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
RevenueTrailing 12 months$62M$0
EBITDAEarnings before interest/tax-$109M-$1.4B
Net IncomeAfter-tax profit-$102M-$1.4B
Free Cash FlowCash after capex-$140M-$1.1B
Gross MarginGross profit ÷ Revenue+97.3%
Operating MarginEBIT ÷ Revenue-178.4%
Net MarginNet income ÷ Revenue-162.9%
FCF MarginFCF ÷ Revenue-2.2%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%
EPS Growth (YoY)Latest quarter vs prior year+11.8%-102.7%
TNGX leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

TNGX leads this category, winning 2 of 2 comparable metrics.
MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
Market CapShares × price$3.2B$32.1B
Enterprise ValueMkt cap + debt − cash$3.1B$31.9B
Trailing P/EPrice ÷ TTM EPS-27.15x-25.39x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue51.47x
Price / BookPrice ÷ Book value/share7.93x17.61x
Price / FCFMarket cap ÷ FCF
TNGX leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

TNGX leads this category, winning 7 of 8 comparable metrics.

TNGX delivers a -50.3% return on equity — every $100 of shareholder capital generates $-50 in annual profit, vs $-83 for RVMD. TNGX carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), TNGX scores 4/9 vs RVMD's 1/9, reflecting mixed financial health.

MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
ROE (TTM)Return on equity-50.3%-83.2%
ROA (TTM)Return on assets-36.3%-59.1%
ROICReturn on invested capital-38.5%-54.3%
ROCEReturn on capital employed-34.0%-53.0%
Piotroski ScoreFundamental quality 0–941
Debt / EquityFinancial leverage0.10x0.10x
Net DebtTotal debt minus cash-$79M-$225M
Cash & Equiv.Liquid assets$112M$384M
Total DebtShort + long-term debt$34M$159M
Interest CoverageEBIT ÷ Interest expense-81.62x
TNGX leads this category, winning 7 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

TNGX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in RVMD five years ago would be worth $52,093 today (with dividends reinvested), compared to $20,539 for TNGX. Over the past 12 months, TNGX leads with a +1774.6% total return vs RVMD's +303.5%. The 3-year compound annual growth rate (CAGR) favors TNGX at 90.1% vs RVMD's 83.5% — a key indicator of consistent wealth creation.

MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
YTD ReturnYear-to-date+164.5%+91.2%
1-Year ReturnPast 12 months+1774.6%+303.5%
3-Year ReturnCumulative with dividends+586.6%+518.1%
5-Year ReturnCumulative with dividends+105.4%+420.9%
10-Year ReturnCumulative with dividends+130.9%+422.7%
CAGR (3Y)Annualised 3-year return+90.1%+83.5%
TNGX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

RVMD leads this category, winning 2 of 2 comparable metrics.

RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than TNGX's 1.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs TNGX's 83.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
Beta (5Y)Sensitivity to S&P 5001.81x1.08x
52-Week HighHighest price in past year$28.41$155.70
52-Week LowLowest price in past year$1.03$34.00
% of 52W HighCurrent price vs 52-week peak+83.1%+97.0%
RSI (14)Momentum oscillator 0–10055.864.2
Avg Volume (50D)Average daily shares traded3.4M3.0M
RVMD leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates TNGX as "Buy" and RVMD as "Buy". Consensus price targets imply 2.5% upside for RVMD (target: $155) vs -3.7% for TNGX (target: $23).

MetricTNGX logoTNGXTango Therapeutic…RVMD logoRVMDRevolution Medici…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$22.75$154.80
# AnalystsCovering analysts1022
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

TNGX leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). RVMD leads in 1 (Risk & Volatility).

Best OverallTango Therapeutics, Inc. (TNGX)Leads 4 of 6 categories
Loading custom metrics...

TNGX vs RVMD: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is TNGX or RVMD a better buy right now?

Analysts rate Tango Therapeutics, Inc.

(TNGX) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TNGX or RVMD?

Over the past 5 years, Revolution Medicines, Inc.

(RVMD) delivered a total return of +420. 9%, compared to +105. 4% for Tango Therapeutics, Inc. (TNGX). Over 10 years, the gap is even starker: RVMD returned +422. 7% versus TNGX's +130. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TNGX or RVMD?

By beta (market sensitivity over 5 years), Revolution Medicines, Inc.

(RVMD) is the lower-risk stock at 1. 08β versus Tango Therapeutics, Inc. 's 1. 81β — meaning TNGX is approximately 67% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Tango Therapeutics, Inc. (TNGX) carries a lower debt/equity ratio of 10% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — TNGX or RVMD?

On earnings-per-share growth, the picture is similar: Tango Therapeutics, Inc.

grew EPS 26. 9% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TNGX or RVMD?

Revolution Medicines, Inc.

(RVMD) is the more profitable company, earning 0. 0% net margin versus -162. 9% for Tango Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -178. 4% for TNGX. At the gross margin level — before operating expenses — TNGX leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — TNGX or RVMD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is TNGX or RVMD better for a retirement portfolio?

For long-horizon retirement investors, Revolution Medicines, Inc.

(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +422. 7% 10Y return). Tango Therapeutics, Inc. (TNGX) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RVMD: +422. 7%, TNGX: +130. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between TNGX and RVMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TNGX is a small-cap high-growth stock; RVMD is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

TNGX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 58%
Run This Screen
Stocks Like

RVMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.